Slide 1: Q2 2026 Highlights
Q2 2026 Highlights July 29, 2026 1 Q2 2026 Financial & Operational Highlights | July 29, 2026
Slide 2: Forward-Looking Statements and Use of Document
Forward-Looking Statements and Use of Document Forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by wor
Slide 3: Q2 2026 Highlights
Q2 2026 Highlights Financial Highlights Operational Highlights • Net sales growth: • Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares. • +7.5% reported, +7.0% operational*/organic* Y/Y • Invested $1.5 billion in MiRus LL
Slide 4: Reported Net Sales by Segment and Business
Reported Net Sales by Segment and Business Q2 2026 Reported Net Sales: $5.442B Net Sales by Business; Segment Percentage of Total Net Sales Cardiovascular MedSurg NM $341M 33% Uro $1.333B $684M $507M $916M Cardiovascular Endo $3.624B $585M $793M $283M ICVT WM EP CRM IO&E Cardiovascular 67% 4 Q2 2026
Slide 5: MedSurg Performance Summary
MedSurg Performance Summary Measure Q2 2026 Q2 2025 Change Y/Y Reported Net Sales $1.818B $1.716B +5.9% Adjusted Operating Margin* 32.9% 35.1% (230 bps) * Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to exclud
Slide 6: Cardiovascular Performance Summary
Cardiovascular Performance Summary Measure Q2 2026 Q2 2025 Change Y/Y Reported Net Sales $3.624B $3.345B +8.3% Adjusted Operating Margin* 33.1% 32.1% +100 bps * Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to
Slide 7: Key Growth Catalysts
Key Growth Catalysts Select new products and data releases Product Launched Product Launch Expected Data Release 2026 2027E 2028E Cardiovascular FRACTURE (Coronary IVL) SEISMIQ™ Coronary IVL ICVT SEISMIQ™ SEISMIQ™ Below-the-Knee IVL THRIVE (RDN) TIVUS™ Intravascular Ultrasound System (RDN) Above-the
Slide 8: Future of Innovation
Future of Innovation Unlocking New Markets for BSX Product 2025E Market Size 2026E 2027E 2028E 2029E Market Growth RDN $1B+ Renal Denervation +DD THRIVE Data TIVUS™ Release Launch 2028E IVL $1B+ Intravascular Lithotripsy +DD SEISMIQ™ SEISMIQ™ SEISMIQ™ 4CE Peripheral ATK Peripheral Coronary Launch BT
Slide 9: Our Approach to Corporate Responsibility
Our Approach to Corporate Responsibility 9 Q2 2026 Financial & Operational Highlights | July 29, 2026
Slide 10: Q2 2026 Net Sales vs. Q2 2025
Q2 2026 Net Sales vs. Q2 2025 Q2 2026 Reported Organic* Growth Net Sales vs Q2 2025 (in millions, except percentages) Endoscopy $793 7% Urology $684 1% Neuromodulation $341 12% MedSurg $1,818 5% Interventional Cardiology and Vascular Therapies $1,333 12% Watchman $507 4% Electrophysiology $916 9% Ca
Slide 11: Income Statement Information
Income Statement Information Non-GAAP Reconciliation Three Months Ended June 30, 2026 (unaudited) Restructuring International Acquisition/ and Investment Emergency Divestiture- Restructuring- Litigation- Portfolio Net Economic Deferred Related Net Related Net Related Net Losses/ EU MDR Powers Act Ta
Slide 12: Working Capital & Cash Flow Metrics
Working Capital & Cash Flow Metrics Days Sales Outstanding (DSO) Free Cash Flow* Jun Mar Dec Sep Jun Q2 Q2 2026 2026 2025 2025 2025 2026 2025 51 52 51 51 51 $1.290B $1.129B Days Inventory on Hand (DIOH) Capital Expenditures Jun Mar Dec Sep Jun Q2 Q2 2026 2026 2025 2025 2025 2026 2025 185 177 168 177
Slide 13: Use of Non-GAAP Measures
Use of Non-GAAP Measures To supplement Boston Scientific’s consolidated financial statements presented on a GAAP basis, the Company discloses certain non- GAAP financial measures. These measures are not in accordance with generally accepted accounting principles in the United States. A reconciliatio
Slide 14: Appendix A Net Sales Detail
Appendix A Net Sales Detail 14 Q2 2026 Financial & Operational Highlights | July 29, 2026
Slide 15: Appendix A - Net Sales Detail - MedSurg
Appendix A - Net Sales Detail - MedSurg Three Months Ended June 30, 2026 and 2025 Year-over-Year Change Impact of Foreign Q2 Q2 Currency (in millions, except percentages) 2026 2025 Reported Basis Fluctuations Operational Basis MEDSURG SEGMENT: ENDOSCOPY UNITED STATES $ 491 $ 456 7.6 % — % 7.6 % INTE
Slide 16: Appendix A - Net Sales Detail - Cardiovascular
Appendix A - Net Sales Detail - Cardiovascular Three Months Ended June 30, 2026 and 2025 Year-over-Year Change Impact of Foreign Q2 Q2 Currency (in millions, except percentages) 2026 2025 Reported Basis Fluctuations Operational Basis CARDIOVASCULAR SEGMENT: Interventional Cardiology & Vascular Thera
Slide 17: Appendix B Additional Information - Statement of Operations
Appendix B Additional Information - Statement of Operations 17 Q2 2026 Financial & Operational Highlights | July 29, 2026
Slide 18: Appendix B - Statement of Operations Profitability Margins
Appendix B - Statement of Operations Profitability Margins Three Months Ended Adjusted Gross Margin 6/30/2026 6/30/2025 Basis Points Change Gross Margin, as reported 70.7 % 67.7 % 300 Non-GAAP adjustments (0.4) % 1.7 % Gross Margin, adjusted 70.3 % 69.4 % 80 Three Months Ended Adjusted Operating Mar
Slide 19: Appendix C Additional Non-GAAP Reconciliations
Appendix C Additional Non-GAAP Reconciliations 19 Q2 2026 Financial & Operational Highlights | July 29, 2026
Slide 20: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Impact of Impact of Foreign Certain Q2 Q2 As Reported Currency Operational Acquisitions/ Organic (in millions, except percentages) 2026 2025 Basis Fluctuations Basis Divestitures(1) Basis ENDOSCOPY $ 793 $ 737 7.6 % (0.7) % 7.0 % — % 7.0 % UROLOGY 684
Slide 21: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended Free Cash Flow (in millions) 6/30/2026 Cash provided by (used for) operating activities $ 1,475 Proceeds on disposals of property, plant and equipment 10 Purchases of property, plant and equipment and internal use software (194) Fre
Slide 22: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations 12 Months Ended Reconciliation of Debt to Adjusted EBITDA (in millions) Q3 2025 Q4 2025 Q1 2026 Q2 2026 6/30/2026 Net income (loss) $ 755 $ 670 $ 1,339 $ 905 $ 3,668 Income tax (benefit) expense 183 30 (176) 155 192 Interest expense 87 90 90 96 363 In
Slide 23: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended June 30, 2026 % of net sales % of net sales of reportable of reportable Adjusted Operating Margin - by Reportable Segment (in millions, except percentages) MedSurg segments Cardiovascular segments Total Net sales, as reported $ 1,81
Slide 24: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended June 30, 2025 % of net sales % of net sales of reportable of reportable Adjusted Operating Margin - by Reportable Segment (in millions, except percentages) MedSurg segments Cardiovascular segments Total Net sales, as reported $ 1,71
Slide 25: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended Adjusted Below-the-Line Expenses (in millions) June 30, 2026 Below-the-line expenses, as reported $ (118) Non-GAAP adjustments (2) Below-the-line expenses, adjusted $ (120) Three Months Ended Adjusted Tax Rate June 30, 2026 Tax Rate
Slide 26: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended June 30, 2026 Interventional Cardiology Net Sales Growth (in millions, except percentages) $ % Net sales growth, as reported $ 849 16.1 % Impact of foreign currency fluctuations (8) (1.1) % Net sales growth, operational 840 14.9 % I
Slide 27: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Three Months Ended Three Months Ended EP U.S. Net Sales Growth June 30, 2026 EP International Net Sales Growth June 30, 2026 Net sales growth, as reported 3.1 % Net sales growth, as reported 22.9 % Impact of foreign currency fluctuations — % Impact of
Slide 28: Reconciliations
Appendix C - Additional Non-GAAP Reconciliations Q3 2026 Estimate Full Year 2026 Estimate Net Sales Guidance (Low) (High) (Low) (High) Reported growth 3.0 % 5.0 % 5.5 % 6.5 % Impact of foreign currency fluctuations — % — % (0.5) % (0.5) % Operational growth 3.0 % 5.0 % 5.0 % 6.0 % Impact of certain
Slide 29: BSX: Acronym Reference Guide
BSX: Acronym Reference Guide AF Atrial Fibrillation CODM Chief Operating Decision Maker CRM Cardiac Rhythm Management DCB Drug Coated Balloon DIOH Days Inventory on Hand DRG Diagnosis-Related Group Reimbursement DSO Days Sales Outstanding EBITDA Earnings Before Interest, Taxes, Depreciation, and EME